Questions? Comments? Send us a message!We discuss a Phase 2a clinical trial investigating the use of intravenous DMT (SPL026) as a fast-acting treatment for major depressive disorder. The research demonstrates that a single dose, paired with psychotherapeutic support, leads to a rapid and significant reduction in symptoms that can last up to three months. Unlike traditional antidepressants that take weeks to work, this short-acting psychedelic provides an immediate effect and was found to be generally safe and well-tolerated by participants. Dr. Steve’s commentary emphasizes that this modern research addresses a forty-year gap in psychedelic studies caused by previous political and regulatory restrictions. Overall, the findings suggest that DMT could offer a highly efficient alternative for patients who do not respond well to conventional therapies.Check out simplyherbals.net and tell them Topics in Palliative Medicine sent you!Support the showThank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related